BRAF V600EPhase 3 (Cohort 3)ASCO GI 2026來源:人工整理

EC+FOLFIRI vs FOLFIRI±bev (1L)

關鍵結果ORR 64.4% vs 39.2%, OR 2.76; 肝 mets ORR 79.1%

FOLFIRI 也行——提供第二個化療骨幹選擇,特別適合 oxaliplatin 禁忌

詳細證據整理

BREAKWATER: Primary Analysis of First-Line (1L) Encorafenib + Cetuximab (EC) + FOLFIRI in BRAF V600E-Mutant mCRC

Authors: Kopetz S, Wasan HS, Yoshino T, Kim TW, Eng C, Van Cutsem E, et al.
Presented at: ASCO GI 2026
Study: BREAKWATER Cohort 3 (Phase 3)
Note: This is a conference presentation. No peer-reviewed journal full text is available.

Study Design

  • EC+FOLFIRI arm: n=73
  • Control (FOLFIRI ± bevacizumab): n=74

Primary Endpoint: Objective Response Rate (ORR)

Endpoint EC+FOLFIRI Control Statistics
ORR (Primary) 64.4% 39.2% OR 2.756, p=0.0011
Complete Response (CR) 4.1% 1.4% --
Partial Response (PR) 60.3% 37.8% --

Primary endpoint was met.

Secondary Endpoints

Endpoint EC+FOLFIRI Control
Time to Response (TTR) 6.9 weeks 7.1 weeks
DOR ≥6 months 57.4% 34.5%
OS HR 0.49 (95% CI: 0.237-1.032) -- trend favoring EC+FOLFIRI

Subgroup Analysis: Liver Metastases

Subgroup EC+FOLFIRI ORR Control ORR Odds Ratio
Patients with liver metastases 79.1% 37.0% 6.44

Safety

The safety profile was consistent with the known profiles of each individual agent. No new safety signals were identified.

Conclusions

EC+FOLFIRI demonstrated a statistically significant improvement in ORR compared with FOLFIRI ± bevacizumab in first-line BRAF V600E-mutant mCRC. The results support EC + chemotherapy as a backbone for first-line treatment, with both mFOLFOX6 and FOLFIRI as viable chemotherapy partners.

本頁僅供醫療專業人員教育與臨床參考,不構成醫療建議;臨床決策請以原始文獻與現行指引為準。

讀者討論

讀者留言是個人意見,不是本站的文獻整理,也沒有經過醫學審核。

載入留言中…

  • GuidelineJNCCN 2026來源:摘要

    NCCN Colon Cancer v3.2026(Guidelines Insights)

    BRAF V600E 晚期治療推薦更新, 晚期治療章節依 biomarker 重組; 新增 fluoropyrimidine 前 DPYD 檢測; 依近期試驗更新非轉移性輔助治療

    NCCN 結腸癌 v3.2026 依 biomarker 重組晚期治療章節,並特別更新 BRAF V600E 推薦,承接 BREAKWATER 證據;另新增化療前 DPYD 檢測建議。Insights 摘要未列推薦等級,細節需對照指引全文

  • Biomarker (exploratory)ESMO 2025來源:人工整理

    EC+mFOLFOX6 vs EC vs SOC

    C2D15 D/ND: 67.1% vs 45.2% vs 37.5%; resistance 6.6% vs 37.9%

    化療骨幹壓制抗藥性克隆——EC+chemo 優於 EC alone 的分子機制

  • Phase 3 RCTNat Med 2025來源:人工整理

    EC+mFOLFOX6 vs SOC (1L)

    ORR 60.9% vs 40.0%, OR 2.44

    BREAKWATER 首報:一線 EC+化療 ORR 達 61%,FDA 加速核准

  • Phase 3 RCT (updated)NEJM 2025來源:人工整理

    EC+mFOLFOX6 vs SOC (1L)

    mPFS 12.8 vs 7.1 mo; mOS 30.3 vs 15.1 mo, HR 0.49

    mOS 30.3 個月——BRAF V600E mCRC 首次追上 BRAF wt 的存活。死亡風險減半

看 BRAF V600E 的全部文獻